Skip to main content

Advertisement

SpringerLink
Log in

Practical Approaches to Management of Children With COVID-19 and Kidney Disease: the Known, Unknown, and the Future

  • Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)
  • Published:
Current Treatment Options in Pediatrics Aims and scope Submit manuscript

Abstract

Purpose of Review

The impact of the COVID-19 pandemic on children has worsened since the evolution of the new variants, causing a substantial negative effect on children with chronic illnesses such as kidney disease. This virus has effects on the kidneys during, as well as after the acute illness, called the ‘long COVID’ phase. In this paper, we review the known facets of COVID-19 illness and vaccine guidance in the pediatric population with kidney disease, highlight the unknown facts, and discuss the future, long-term implications of the disease on children.

Recent Findings

COVID-19 affects children with no prior history of kidney disease, as well as children with CKD, though manifestations can be complex in the CKD population. Vaccination and booster dosage may be beneficial in children with CKD, particularly those on immunosuppression. Long COVID can be troublesome in children and might aggravate kidney damage in the CKD population; however, more data is needed.

Summary

Continuous and careful monitoring, attentiveness to symptoms, a high index of suspicion, and a multidisciplinary approach might be effective in managing these children. Further research is needed to shed light on the complications and optimal care of the pediatric population with kidney disease, affected by COVID-19.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. COVID 19 dashboard by CSSE at Johns Hopkins University. https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6. [cited 2022 20 October].

  2. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702. https://doi.org/10.1542/peds.2020-0702.

  3. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109(6):1088–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Stewart DJ, Hartley JC, Johnson M, Marks SD, du Pré P, Stojanovic J. Renal dysfunction in hospitalised children with COVID-19. Lancet Child Adolesc Health. 2020;4(8):e28–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kamidani S, Rostad CA, Anderson EJ. COVID-19 vaccine development: a pediatric perspective. Curr Opin Pediatr. 2021;33(1):144–51.

    Article  CAS  PubMed  Google Scholar 

  6. CDC. Mortality and morbidity report. https://www.cdc.gov/mmwr/volumes/70/wr/mm7036e2.htm?s_cid=mm7036e2_w [cited 2021 Oct 7].

  7. Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31(7):1380–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet. 2020;395(10223):497–506.

    Article  CAS  PubMed  Google Scholar 

  9. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen YT, Shao SC, Hsu CK, Wu IW, Hung MJ, Chen YC. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care. 2020;24(1):346.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Basalely A, Gurusinghe S, Schneider J, Shah SS, Siegel LB, Pollack G, et al. Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19. Kidney Int. 2021;100(1):138–45. This is a a retrospective study of patients 18 years of age and under admitted to 4 centers. This cohort included 152 patients; 97 acute-COVID-19 and 55 with MIS-C associated with COVID-19. AKI occurred in 8 with acute-COVID-19 and in 10 with MIS-C. Patients with MIS-C and AKI had significantly greater rates of systolic dysfunction, compared to those without (80% vs 49%).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kari JA, Shalaby MA, Albanna AS, Alahmadi TS, Alherbish A, Alhasan KA. Acute kidney injury in children with COVID-19: a retrospective study. BMC Nephrol. 2021;22(1):202. This is a multicenter retrospective cohort study from three tertiary centers in 89 children with confirmed COVID-19. AKI occurred in 1/5th of children with SARS-CoV-2 infection requiring hospital admission, with 1/3rd of those requiring PICU. No patient required renal replacement therapy. Residual renal impairment at discharge occurred in 9 % of patients and was significantly influenced by the presence of hypotension, hypoxia, heart failure, acute respiratory distress, hypernatremia, abnormal liver profile, high C-reactive protein, and positive blood culture.

  13. Wang X, Chen X, Tang F, Luo W, Fang J, Qi C, et al. Be aware of acute kidney injury in critically ill children with COVID-19. Pediatr Nephrol. 2021;36(1):163–9.

    Article  PubMed  Google Scholar 

  14. Bjornstad EC, Krallman KA, Askenazi D, Zappitelli M, Goldstein SL, Basu RK, et al. Preliminary assessment of acute kidney injury in critically ill children associated with SARS-CoV-2 infection: a multicenter cross-sectional analysis. Clin J Am Soc Nephrol : CJASN. 2021;16(3):446–8. This is a multicenter, point-prevalence AKI study among critically ill children with COVID-19 including children age 1 month- 18 years. Of 106 included children, almost half developed AKI: 47% of those had stage 1, 23% had stage 2, and 30% had stage 3. No child received dialysis.

    Article  PubMed  Google Scholar 

  15. Malieckal DA, Uppal NN, Ng JH, Jhaveri KD, Hirsch JS, Consortium NNC-R. Electrolyte abnormalities in patients hospitalized with COVID-19. Clin Kidney J. 2021;14(6):1704–7. This study reported electrolyte abnormalities at admission on 10,385 patients. Overall, hyponatremia was the most commonly identified disorder in 37.5%, followed by hypochloremia (26.0%) and hypocalcemia (18.3%). Other abnormalities were hypernatremia, hyperphosphatemia and hypermagnesemia.

  16. Ruiz-Sánchez JG, Núñez-Gil IJ, Cuesta M, Rubio MA, Maroun-Eid C, Arroyo-Espliguero R, et al. Prognostic impact of hyponatremia and hypernatremia in COVID-19 pneumonia. A HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry analysis. Front Endocrinol (Lausanne). 2020;11:599255.

    Article  PubMed  Google Scholar 

  17. Longhitano E, Nardi C, Calabrese V, Messina R, Mazzeo G, Venanzi Rullo E, et al. Hypernatraemia and low eGFR at hospitalization in COVID-19 patients: a deadly combination. Clin Kidney J. 2021;14(10):2227–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Wan ER, Woolfson RG, Greenwood R, Walsh SB. Transient renal tubular syndromes associated with acute COVID-19 disease. Kidney Int Rep. 2020;5(9):1610–1.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Diorio C, McNerney KO, Lambert M, Paessler M, Anderson EM, Henrickson SE, et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020;4(23):6051–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Levenson E, Shepherd TN, Aviles D, Craver R, Ehlayel A, Love GL, et al. De novo collapsing glomerulopathy in a pediatric kidney transplant recipient with COVID-19 infection. Pediatr Transplant. 2021;25(4):e14013.

    Article  CAS  PubMed  Google Scholar 

  21. Dalkiran T, Kandur Y, Kara EM, Dagoglu B, Taner S, Oncu D. Thrombotic microangiopathy in a severe pediatric case of COVID-19. Clin Med Insights Pediatr. 2021;15:11795565211049896.

    Article  PubMed  PubMed Central  Google Scholar 

  22. May RM, Cassol C, Hannoudi A, Larsen CP, Lerma EV, Haun RS, Braga JR, Hassen SI, Wilson J, VanBeek C, Vankalakunti M, Barnum L, Walker PD, Bourne TD, Messias NC, Ambruzs JM, Boils CL, Sharma SS, Cossey LN, Baxi PV, Palmer M, Zuckerman JE, Walavalkar V, Urisman A, Gallan AJ, Al-Rabadi LF, Rodby R, Luyckx V, Espino G, Santhana-Krishnan S, Alper B, Lam SG, Hannoudi GN, Matthew D, Belz M, Singer G, Kunaparaju S, Price D, Chawla S, Rondla C, Abdalla MA, Britton ML, Paul S, Ranjit U, Bichu P, Williamson SR, Sharma Y, Gaspert A, Grosse P, Meyer I, Vasudev B, El Kassem M, Velez JCQ, Caza TN. A multi-center retrospective cohort study defines the spectrum of kidney pathology in Coronavirus 2019 Disease (COVID-19). Kidney Int. 2021;100(6):1303–15. https://doi.org/10.1016/j.kint.2021.07.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Marlais M, Wlodkowski T, Vivarelli M, Pape L, Tönshoff B, Schaefer F, et al. The severity of COVID-19 in children on immunosuppressive medication. Lancet Child Adolesc Health. 2020;4(7):e17–8. This study reported data from 18 children with CKD and kideny transplant. Even children receiving immunosuppressive treatment for various indications appear to have a mild clinical course of COVID-19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Marlais M, Wlodkowski T, Al-Akash S, Ananin P, Bandi VK, Baudouin V, Boyer O, Vásquez L, Govindan S, Hooman N, Ijaz I, Loza R, Melgosa M, Pande N, Pape L, Saha A, Samsonov D, Schreuder MF, Sharma J, Siddiqui S, Sinha R, Stewart H, Tasic V, Tönshoff B, Twombley K, Upadhyay K, Vivarelli M, Weaver DJ, Woroniecki R, Schaefer F, Tullus K. COVID-19 in children treated with immunosuppressive medication for kidney diseases. Arch Dis Child. 2020;106(8):798–801. https://doi.org/10.1136/archdischild-2020-320616.

    Article  PubMed  Google Scholar 

  25. Morello W, Mastrangelo A, Guzzo I, Cusinato L, Annicchiarico Petruzzelli L, Benevenuta C, et al. Prevalence of SARS-CoV-2-IgG antibodies in children with CKD or immunosuppression. Clin J Am Soc Nephrol : CJASN. 2021;16(7):1097–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Harambat J, Allard L, Godron-Dubrasquet A. Relapse rate of nephrotic syndrome in the time of COVID-19. Pediatr Nephrol. 2021;36(1):211–2.

    Article  PubMed  Google Scholar 

  27. Alvarado A, Franceschi G, Resplandor E, Sumba J, Orta N. COVID-19 associated with onset nephrotic syndrome in a pediatric patient: coincidence or related conditions? Pediatr Nephrol. 2021;36(1):205–7.

    Article  PubMed  Google Scholar 

  28. Shah SA, Carter HP. New-onset nephrotic syndrome in a child associated with COVID-19 infection. Front Pediatr. 2020;8:471.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Morgan KM, Imani PD. Case report: a 5-year-old with new onset nephrotic syndrome in the setting of COVID-19 infection. BMC Nephrol. 2021;22(1):323.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Cristoforo T, McKinley G, Ambrosio P. Saddle pulmonary embolism in a pediatric patient with nephrotic syndrome and recent COVID-19 pneumonia: A case report. Am J Emerg Med. 2021;48:376.e1-376.e2. https://doi.org/10.1016/j.ajem.2021.04.014.

  31. AlGhoozi DA, AlKhayyat HM. A child with Henoch-Schonlein purpura secondary to a COVID-19 infection. BMJ Case Rep. 2021;14(1):e239910. https://doi.org/10.1136/bcr-2020-239910.

  32. Hoskins B, Keeven N, Dang M, Keller E, Nagpal R. A child with COVID-19 and immunoglobulin A vasculitis. Pediatr Ann. 2021;50(1):e44–8.

    Article  PubMed  Google Scholar 

  33. Jacobi M, Lancrei HM, Brosh-Nissimov T, Yeshayahu Y. Purpurona: a novel report of COVID-19-related Henoch-Schonlein purpura in a child. Pediatr Infect Dis J. 2021;40(2):e93–4.

    Article  PubMed  Google Scholar 

  34. Kumar G, Pillai S, Norwick P, Bukulmez H. Leucocytoclastic vasculitis secondary to COVID-19 infection in a young child. BMJ Case Rep. 2021;14(4):e242192. https://doi.org/10.1136/bcr-2021-242192.

  35. Fireizen Y, Shahriary C, Imperial ME, Randhawa I, Nianiaris N, Ovunc B. Pediatric P-ANCA vasculitis following COVID-19. Pediatr Pulmonol. 2021;56(10):3422–4.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Powell WT, Campbell JA, Ross F, Peña Jiménez P, Rudzinski ER, Dickerson JA. Acute ANCA vasculitis and asymptomatic COVID-19. Pediatrics. 2021;147(4):e2020033092. https://doi.org/10.1542/peds.2020-033092.

  37. Faria BCD, Sacramento LGG, Filipin CSA, Cruz AFD, Nagata SN, Silva ACSE. An analysis of chronic kidney disease as a prognostic factor in pediatric cases of COVID-19. J Bras Nefrol. 2021;43(3):400–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Krishnasamy S, Mantan M, Mishra K, Kapoor K, Brijwal M, Kumar M, et al. SARS-CoV-2 infection in children with chronic kidney disease. Pediatr Nephrol. 2021. This is a retrospective study of pediatric patients with CKD. This study included pediatric patients with nephrotic syndrome, CKD stages 1–4, CKD 5D, and CKD 5T. 19% patients developed moderate or severe COVID-19. 21.6% had severe complications, including AKI stage 2–3, encephalopathy, respiratory failure, and shock. Eight of twelve patients with severe AKI required dialysis.

  39. Mastrangelo A, Morello W, Vidal E, Guzzo I, Annicchiarico Petruzzelli L, Benetti E, et al. Impact of COVID-19 pandemic in children with CKD or immunosuppression. Clin J Am Soc Nephrol : CJASN. 2021;16(3):449–51.

    Article  CAS  PubMed  Google Scholar 

  40. Melgosa M, Madrid A, Alvárez O, Lumbreras J, Nieto F, Parada E, et al. SARS-CoV-2 infection in Spanish children with chronic kidney pathologies. Pediatr Nephrol. 2020;35(8):1521–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Rawson A, Wilson AC, Schwaderer AL, Spiwak E, Johnston B, Anderson S, et al. Coronavirus disease 2019 (COVID-19) in two pediatric patients with kidney disease on chronic immunosuppression: A case series. Hemodial Int. 2021;25(1):E1–5.

    Article  PubMed  Google Scholar 

  42. Basalely A, Brathwaite K, Duong MD, Liu D, Mazo A, Xie Y, et al. COVID-19 in children with kidney disease: a report of 2 cases. Kidney Med. 2021;3(1):120–3.

    Article  PubMed  Google Scholar 

  43. Cravedi P, Mothi SS, Azzi Y, Haverly M, Farouk SS, Pérez-Sáez MJ, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(11):3140–8.

    Article  CAS  Google Scholar 

  44. Guillen E, Pineiro GJ, Revuelta I, Rodriguez D, Bodro M, Moreno A, et al. Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(7):1875–8.

    Article  CAS  Google Scholar 

  45. Bush R, Johns F, Acharya R, Upadhyay K. Mild COVID-19 in a pediatric renal transplant recipient. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(10):2942–5.

    Article  CAS  Google Scholar 

  46. Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, et al. Covid-19 and kidney transplantation. N Engl J Med. 2020;382(25):2475–7.

    Article  PubMed  Google Scholar 

  47. Varnell C, Harshman LA, Smith L, Liu C, Chen S, Al-Akash S, et al. COVID-19 in pediatric kidney transplantation: the improving renal outcomes collaborative. Am J Transplant. 2021;21(8):2740–8. This is a prospective cohort study through the improving renal outcomes collaborative collected clinical outcome data about COVID-19 in pediatric kidney transplant (KT) patients. 24 (8.5%) patients tested positive, of which 15 (63%) were symptomatic. Of the COVID-19-positive patients, 16 were managed as outpatients, 6 received non-ICU inpatient care and 2 were admitted to the ICU. There were no episodes of respiratory failure, allograft loss, or death associated with COVID-19. Pediatric KT patients in the United States had a low estimated incidence of COVID-19 disease and excellent short-term outcomes.

    Article  CAS  PubMed  Google Scholar 

  48. Varnell C Jr, Harshman LA, Liu C, Smith L, Al-Akash S, Barletta GM, Brakeman P, Chaudhuri A, Fadakar P, Galea L, Garro R, Gluck C, Kershaw DB, Matossian D, Patel HP, Peterson C, Pruette C, Ranabothu S, Rodig N, Singer P, Sebestyen VanSickle J, Weng PL, Danziger-Isakov L, Seifert ME, Hooper DK. COVID-19 in pediatric kidney transplantation: a follow-up report of the Improving Renal Outcomes Collaborative. Pediatr Nephrol. 2023;38(2):537–47. https://doi.org/10.1007/s00467-022-05570-w.

    Article  PubMed  Google Scholar 

  49. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347–58.

    Article  CAS  PubMed  Google Scholar 

  50. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.

    Article  CAS  PubMed  Google Scholar 

  51. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383(4):334–46.

    Article  CAS  PubMed  Google Scholar 

  52. Raina R, Chakraborty R, Mawby I, Agarwal N, Sethi S, Forbes M. Critical analysis of acute kidney injury in pediatric COVID-19 patients in the intensive care unit. Pediatr Nephrol. 2021;36(9):2627–38.

    Article  PubMed  PubMed Central  Google Scholar 

  53. NIH. Clinical spectrum of SARS-CoV-2 infection. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/. [cited.2021.Oct.8].

  54. CDC. COVID19 information for pediatric healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html. [cited.2021.Oct.8].

  55. Kronbichler A, Gauckler P, Windpessl M, Il Shin J, Jha V, Rovin BH, et al. COVID-19: implications for immunosuppression in kidney disease and transplantation. Nat Rev Nephrol. 2020;16(7):365–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. FDA. FDA expands authorization of two monoclonal antibodies for treatment and post-exposure prevention of COVID-19 to younger pediatric patients, including newborns. https://www.fda.gov/news-events/press-announcements/fda-expands-authorization-two-monoclonal-antibodies-treatment-and-post-exposure-prevention-covid-19. Last accessed on Feb 3, 2022. 2021.

  57. Adamsick ML, Gandhi RG, Bidell MR, Elshaboury RH, Bhattacharyya RP, Kim AY, et al. Remdesivir in patients with acute or chronic kidney disease and COVID-19. J Am Soc Nephrol. 2020;31(7):1384–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384(8):693–704.

    Article  CAS  PubMed  Google Scholar 

  59. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, Szewczyk LJ, et al. Molnupiravir, an oral antiviral treatment for COVID-19. medRxiv. 2021. https://doi.org/10.1101/2021.06.17.21258639.

  62. Yan G, Zhou J, Zhu H, Chen Y, Lu Y, Zhang T, et al. The feasibility, safety, and efficacy of Paxlovid treatment in SARS-CoV-2-infected children aged 6–14 years: a cohort study. Annal Trans Med. 2022;10(11):619.

    Article  CAS  Google Scholar 

  63. NIH. National Institutes of Health. COVID-19 treatment guidelines: special considerations in children. Available. https://www.covid19treatmentguidelines.nih.gov/special-populations/children/externalicon. [cited 2021 Oct 8].

  64. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost : JTH. 2020;18(5):1094–9.

    Article  CAS  PubMed  Google Scholar 

  65. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC. [cited 2021 Oct 8].

  66. CDC. Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021.Hospitalizations associated with COVID-19 among children and adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021 | MMWR (cdc.gov). [cited 2021 Oct 8].

  67. Newsletter A. CDC: Delta variant causing increase in pediatric COVID-19 cases, not severity. CDC: Delta variant causing increase in pediatric COVID-19 cases, not severity | American Academy of Pediatrics (aappublications.org). [cited 2021 Oct 8].

  68. https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interactive/children.html [cited 2022 Oct 29].

  69. CDC. Vaccinating dialysis patients and healthcare personnel. Vaccinating Dialysis Patients and Healthcare Personnel | CDC. [cited 2021 Oct 8].

  70. Frenck RW, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al. Safety, immunogenicity, and efficacy of the BNT162b2 COVID-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. This is a multinational, placebo-controlled, observer-blinded trial, with a total of 2260 adolescent participants in a 1:1 ratio received two injections, 21 days apart, of 30 μg of BNT162b2 or placebo. This study reported that geometric mean ratio of SARS-CoV-2 50% neutralizing titers after dose 2 in12-to-15-year-old participants relative to 16-to-25-year-old participants was 1.76

    Article  CAS  PubMed  Google Scholar 

  71. Glenn DA, Hegde A, Kotzen E, Walter EB, Kshirsagar AV, Falk R, et al. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease. Kidney Int Rep. 2021;6(5):1407–10.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Hou YC, Lu KC, Kuo KL. The efficacy of COVID-19 vaccines in chronic kidney disease and kidney transplantation patients: a narrative review. Vaccines (Basel). 2021;9(8):885. https://doi.org/10.3390/vaccines9080885.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Danthu C, Hantz S, Dahlem A, Duval M, Ba B, Guibbert M, et al. Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients. J Am Soc Nephrol. 2021;32(9):2153–8. This study investigated early serological response after COVID-19 vaccination in 78 patients undergoing hemodialysis, 74 kidney transplant recipients, and 7 healthy controls received the Pfizer/BioNTech (BNT162b2) mRNA vaccine. Results showed that postvaccination humoral response is strongly inhibited by immunosuppressant therapy in kidney transplant recipients, and is reduced by the uremic condition in patients undergoing hemodialysis.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, et al. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine. 2021;70:10352.

    Article  Google Scholar 

  75. Jahn M, Korth J, Dorsch O, Anastasiou OE, Sorge-Hädicke B, Tyczynski B, Gäckler A, Witzke O, Dittmer U, Dolff S, Wilde B, Kribben A. Humoral response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in patients on hemodialysis. Vaccines (Basel). 2021;9(4):360. https://doi.org/10.3390/vaccines9040360.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Longlune N, Nogier MB, Miedougé M, Gabilan C, Cartou C, Seigneuric B, et al. High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant. 2021;36(9):1704–9.

    Article  CAS  PubMed  Google Scholar 

  77. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661–2.

    Article  PubMed  Google Scholar 

  79. Crane C, Phebus E, Ingulli E. Immunologic response of mRNA SARS-CoV-2 vaccination in adolescent kidney transplant recipients. Pediatr Nephrol. 2021. This study reports the vaccine response of m-RNA vaccine in 25 adolescents with kidney transplant on variety of immunosupressive agents. This study showed that though the vaccine response rate is less than general population, but better thab adult kidney transplant recipients.

  80. Haskin O, Ashkenazi-Hoffnung L, Ziv N, Borovitz Y, Dagan A, Levi S, et al. Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients. Transplantation. 2021;105(11):e226–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. CDC. Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html.

  82. CDC. Clinical considerations for Pfizer-BioNTech COVID-19 vaccination in adolescents. Clinical considerations for Pfizer-BioNTech COVID-19 vaccination in adolescents (cdc.gov). [cited 2021 Oct 9].

  83. Spiera R, Jinich S, Jannat-Khah D. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. Ann Rheum Dis. 2021;80(10):1357–9.

    Article  CAS  PubMed  Google Scholar 

  84. Santosa A, Xu C, Arkachaisri T, Kong KO, Lateef A, Lee TH, et al. Recommendations for COVID-19 vaccination in people with rheumatic disease: developed by the Singapore Chapter of Rheumatologists. Int J Rheum Dis. 2021;24(6):746–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after COVID-19 vaccination in a large health care organization. N Engl J Med. 2021;385(23):2132–9.

    Article  CAS  PubMed  Google Scholar 

  86. Block JP, Boehmer TK, Forrest CB, Carton TW, Lee GM, Ajani UA, et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(14):517–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Hanna C, Herrera Hernandez LP, Bu L, Kizilbash S, Najera L, Rheault MN, et al. IgA nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the Pfizer COVID-19 vaccine. Kidney Int. 2021;100(3):705–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Li NL, Coates PT, Rovin BH. COVID-19 vaccination followed by activation of glomerular diseases: does association equal causation? Kidney Int. 2021. This article describes a variety of COVID-19 vaccine associated glomerular diseases (CAVGD). It reports the association of m-RNA based vaccines with activation or reactivation of CAVGD. It also reports that there is no current evidence to state that vaccination with one vaccine platform is better than the other.

  89. Kudose S, Friedmann P, Albajrami O, D’Agati VD. Histologic correlates of gross hematuria following Moderna COVID-19 vaccine in patients with IgA nephropathy. Kidney Int. 2021;100(2):468–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Rahim SEG, Lin JT, Wang JC. A case of gross hematuria and IgA nephropathy flare-up following SARS-CoV-2 vaccination. Kidney Int. 2021;100(1):238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Perrin P, Bassand X, Benotmane I, Bouvier N. Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy. Kidney Int. 2021;100(2):466–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Negrea L, Rovin BH. Gross hematuria following vaccination for severe acute respiratory syndrome coronavirus 2 in 2 patients with IgA nephropathy. Kidney Int. 2021;99(6):1487.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Tan HZ, Tan RY, Choo JCJ, Lim CC, Tan CS, Loh AHL, et al. Is COVID-19 vaccination unmasking glomerulonephritis? Kidney Int. 2021;100(2):469–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Lim CC, Choo J, Tan CS. COVID-19 vaccination in immunoglobulin A nephropathy. Am J Kidney Dis. 2021;78(4):617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Aydın MF, Yıldız A, Oruç A, Sezen M, Dilek K, Güllülü M, et al. Relapse of primary membranous nephropathy after inactivated SARS-CoV-2 virus vaccination. Kidney Int. 2021;100(2):464–5.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Da Y, Goh GH, Khatri P. A case of membranous nephropathy following Pfizer-BioNTech mRNA vaccination against COVID-19. Kidney Int. 2021;100(4):938–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Leclerc S, Royal V, Lamarche C, Laurin LP. Minimal change disease with severe acute kidney injury following the Oxford-AstraZeneca COVID-19 vaccine: a case report. Am J Kidney Dis. 2021;78(4):607–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Klomjit N, Alexander MP, Fervenza FC, Zoghby Z, Garg A, Hogan MC, Nasr SH, Minshar MA, Zand L. COVID-19 vaccination and glomerulonephritis. Kidney Int Rep. 2021;6(12):2969–78. https://doi.org/10.1016/j.ekir.2021.09.008.

    Article  PubMed  PubMed Central  Google Scholar 

  99. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int. 2021;100(2):473–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Shakoor MT, Birkenbach MP, Lynch M. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis. 2021;78(4):611–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Tuschen K, Bräsen JH, Schmitz J, Vischedyk M, Weidemann A. Relapse of class V lupus nephritis after vaccination with COVID-19 mRNA vaccine. Kidney Int. 2021;100(4):941–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. CDC. How to address COVID-19 vaccine misinformation. https://www.cdc.gov/vaccines/covid-19/health-departments/addressing-vaccine-misinformation.html. [cited 2021 Oct 9].

  103. CDC. How to talk with parents about COVID-19 vaccination. https://www.cdc.gov/vaccines/covid-19/hcp/pediatrician.html. [cited 2021 Oct 9].

  104. CDC. Talking with patients about COVID-19 vaccination. https://www.cdc.gov/vaccines/covid-19/hcp/engaging-patients.html. [cited 2021 Oct 9].

  105. CDC. How to talk with patients who are immunocompromised. https://www.cdc.gov/vaccines/covid-19/hcp/immunocompromised-patients.html. [cited 2021 Oct 9].

  106. Jiao WY, Wang LN, Liu J, Fang SF, Jiao FY, Pettoello-Mantovani M, et al. Behavioral and emotional disorders in children during the COVID-19 epidemic. J Pediatr. 2020;221:264-6.e1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. CDC. Post-COVID conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/. [cited 2021 Oct 8].

  108. News A. AAP urges post-COVID-19 follow-up to monitor for residual symptoms. https://www.aappublications.org/news/2021/08/02/post-acute-covid-080221. [cited 2021 Oct 8].

  109. Buonsenso D, Munblit D, De Rose C, Sinatti D, Ricchiuto A, Carfi A, et al. Preliminary evidence on long COVID in children. Acta Paediatr. 2021;110(7):2208–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Osmanov IM, Spiridonova E, Bobkova P, Gamirova A, Shikhaleva A, Andreeva M, et al. Risk factors for long COVID in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study. Eur Respir J. 2021. This is a prospective cohort study of 518 children (≤18 years old) with confirmed COVID-19 who were followed up after hospitalization. 126 children reported persistence symptoms 5 months after the disease. This study reported the risk factors for persistent symptoms: older age and a history of allergic diseases.

  111. Ludvigsson JF. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021;110(3):914–21.

    Article  CAS  PubMed  Google Scholar 

  112. Yusuke Miyazato VOP, Shinya Tsuzuki , Profile VO, Shinichiro Morioka , Mari Terda , al e. Risk factors associated with development and persistence of long COVID. 2021 [cited 2021 Oct 8].

  113. Renal, and, urology, news. ‘long COVID’ raises kidney damage risk. ‘Long COVID’ raises kidney damage risk - renal and urology news. [cited 2021 Oct 8].

  114. Thomson H. Children with long covid. New Sci. 2021;249(3323):10–1.

    Article  PubMed  PubMed Central  Google Scholar 

  115. Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, Rezek SA, Spruit MA, Vehreschild J, Siegerink B. The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1):2001494. https://doi.org/10.1183/13993003.01494-2020.

  116. Hillis SD, Blenkinsop A, Villaveces A, Annor FB, Liburd L, Massetti GM, Demissie Z, Mercy JA, Nelson CA 3rd, Cluver L, Flaxman S, Sherr L, Donnelly CA, Ratmann O, Unwin HJT. COVID-19-associated orphanhood and caregiver death in the United States. Pediatrics. 2021:e2021053760. https://doi.org/10.1542/peds.2021-053760.

  117. CDC. Guidance for COVID-19 prevention in K-12 Schools. https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/k-12-guidance.html. 2021 [cited 2021 Oct 8].

  118. Robinson C, Ruhl M, Kirpalani A, Alabbas A, Noone D, Teoh CW, et al. Management of canadian pediatric patients with glomerular diseases during the COVID-19 pandemic: recommendations from the Canadian Association of Pediatric Nephrologists COVID-19 rapid response team. Can J Kidney Health Dis. 2020;7:2054358120970713.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Ashoor I, Weidemann D, Elenberg E, Halbach S, Harshman L, Kula A, Mahan JD, Nada A, Quiroga A, Mahon AR, Smith J, Somers M, Brophy PD; ASPN Workforce Summit Action Groups. The pediatric nephrology workforce crisis: a call to Action. J Pediatr. 2021;239:5-10.e4. https://doi.org/10.1016/j.jpeds.2021.03.033.

  120. Boyle SM, Washington R, McCann P, Koul S, McLarney B, Gadegbeku CA. The nephrology nursing shortage: insights from a pandemic. Am J Kidney Dis. 2022;79(1):113–6. https://doi.org/10.1053/j.ajkd.2021.07.007.

    Article  PubMed  Google Scholar 

  121. Pivert KA, Boyle SM, Halbach SM, Chan L, Shah HH, Waitzman JS, et al. Impact of the COVID-19 pandemic on nephrology fellow training and well-being in the United States: a national survey. J Am Soc Nephrol. 2021;32(5):1236–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Beckwith H, Nimmo A, Savino M, Selvaskandan H, Graham-Brown M, Medcalf J, et al. Impact of the COVID-19 pandemic on training, morale and well-being among the UK renal workforce. Kidney Int Rep. 2021;6(5):1433–6.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Wall AE, Pruett T, Stock P, Testa G. Coronavirus disease 2019: Utilizing an ethical framework for rationing absolutely scarce health-care resources in transplant allocation decisions. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg. 2020;20(9):2332–6.

    Article  CAS  Google Scholar 

  124. Fisher M, Prudhvi K, Brogan MLG. Providing care to patients with AKI and COVID-19 infection: experience of front-line nephrologists in New York. Kidney360. 2020;1(6):544–8.

    Article  PubMed  PubMed Central  Google Scholar 

  125. Antiel RM, Curlin FA, Persad G, White DB, Zhang C, Glickman A, Emanuel EJ, Lantos JD. Should pediatric patients be prioritized when rationing life-saving treatments during COVID-19 pandemic. Pediatrics. 2020;146(3):e2020012542. https://doi.org/10.1542/peds.2020-012542.

  126. Martin DE, Parsons JA, Caskey FJ, Harris DCH, Jha V. Ethics of kidney care in the era of COVID-19. Kidney Int. 2020;98(6):1424–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Xu JJ, Chen JT, Belin TR, Brookmeyer RS, Suchard MA, Ramirez CM. Racial and ethnic disparities in years of potential life lost attributable to COVID-19 in the United States: an analysis of 45 states and the District of Columbia. Int J Environ Res Public Health. 2021;18(6):2921. https://doi.org/10.3390/ijerph18062921.

    Article  PubMed  PubMed Central  Google Scholar 

  128. Nguyen LH, Joshi AD, Drew DA, Merino J, Ma W, Lo CH, Kwon S, Wang K, Graham MS, Polidori L, Menni C, Sudre CH, Anyane-Yeboa A, Astley CM, Warner ET, Hu CY, Selvachandran S, Davies R, Nash D, Franks PW, Wolf J, Ourselin S, Steves CJ, Spector TD, Chan AT. Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake. medRxiv [Preprint]. Nat Commun. 2022;13(1):636. https://doi.org/10.1101/2021.02.25.21252402.

  129. Times NY, Holder J. Tracking coronavirus vaccinations around the world. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html. [cited 2021 Oct 8].

Download references

Author information

Authors and Affiliations

  1. East Tennessee Children’s Hospital, Knoxville, TN, USA

    Sai Sudha Mannemuddhu MD

  2. Department of Medicine, University of Tennessee Health Science Center-College of Medicine, Knoxville, TN, USA

    Sai Sudha Mannemuddhu MD

  3. Department of Pediatric Nephrology, Our Lady of the Lake Children’s Hospital, Baton Rouge, LA, USA

    Ashley Rawson MD

  4. Division of Pediatric Nephrology, Department of Pediatrics, Emory University and Children’s Healthcare of Atlanta, 2015 Uppergate Dr. NE, 30322, Atlanta, GA, USA

    Roshan P. George MD

Authors
  1. Sai Sudha Mannemuddhu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley Rawson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roshan P. George MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roshan P. George MD.

Ethics declarations

Conflict of interest

Mannemuddhu Sai Sudha, Rawson Ashley, and George Roshan P. each declare no potential conflicts of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Pediatric Nephrology

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mannemuddhu, S.S., Rawson, A. & George, R.P. Practical Approaches to Management of Children With COVID-19 and Kidney Disease: the Known, Unknown, and the Future. Curr Treat Options Peds 9, 59–80 (2023). https://doi.org/10.1007/s40746-023-00267-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40746-023-00267-0

Keywords

Search

Navigation